| Nicergoline | hsa00030 | Pentose phosphate pathway | 3.06E-04 | 3 | P60891, P51854, P37837 | PRPS1, TKTL1, TALDO1 | More | |
| Nicergoline | hsa00052 | Galactose metabolism | 1.06E-03 | 2 | P06280, O43451 | GLA, MGAM | More | |
| Nicergoline | hsa00190 | Oxidative phosphorylation | 2.29E-02 | 2 | Q16718, O14521 | NDUFA5, SDHD | More | |
| Nicergoline | hsa00240 | Pyrimidine metabolism | 2.20E-02 | 3 | P21589, P32320, P04183 | NT5E, CDA, TK1 | More | |
| Nicergoline | hsa00500 | Starch and sucrose metabolism | 9.19E-06 | 3 | O43451, P46976, P06737 | MGAM, GYG1, PYGL | More | |
| Nicergoline | hsa00590 | Arachidonic acid metabolism | 3.85E-02 | 2 | P11712, P09960 | CYP2C9, LTA4H | More | |
| Nicergoline | hsa00591 | Linoleic acid metabolism | 4.07E-02 | 1 | P11712 | CYP2C9 | More | |
| Nicergoline | hsa00630 | Glyoxylate and dicarboxylate metabolism | 4.29E-03 | 2 | P40925, P15104 | MDH1, GLUL | More | |
| Nicergoline | hsa00730 | Thiamine metabolism | 2.39E-05 | 2 | P05186, P24666 | ALPL, ACP1 | More | |
| Nicergoline | hsa00770 | Pantothenate and CoA biosynthesis | 1.15E-02 | 2 | O95498, Q9NRN7 | VNN2, AASDHPPT | More | |
| Nicergoline | hsa00790 | Folate biosynthesis | 4.74E-02 | 2 | P07101, P42330 | TH, AKR1C3 | More | |
| Nicergoline | hsa00980 | Metabolism of xenobiotics by cytochrome P450 | 9.14E-03 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Nicergoline | hsa00982 | Drug metabolism - cytochrome P450 | 9.14E-03 | 2 | P11712, P78417 | CYP2C9, GSTO1 | More | |
| Nicergoline | hsa00983 | Drug metabolism - other enzymes | 7.78E-04 | 3 | P04183, P32320, P05164 | TK1, CDA, MPO | More | |
| Nicergoline | hsa01100 | Metabolic pathways | 4.43E-02 | 23 | Q9NR34, P05089, P32320, P22748, P55809, P06280, Q16875, O43286, O43451, P05186, P24666, Q9HCC0, P33121, P57054, Q9UNP4, Q9BX95, P32321, Q9BPW9, O75911, Q9UHY7, P43490, P46976, P06737 | MAN1C1, ARG1, CDA, CA4, OXCT1, GLA, PFKFB3, B4GALT5, MGAM, ALPL, ACP1, MCCC2, ACSL1, PIGP, ST3GAL5, SGPP1, DCTD, DHRS9, DHRS3, ENOPH1, PBEF1, GYG1, PYGL | More | |
| Nicergoline | hsa01200 | Carbon metabolism | 4.32E-02 | 3 | P51854, P37837, P60891 | TKTL1, TALDO1, PRPS1 | More | |
| Nicergoline | hsa01230 | Biosynthesis of amino acids | 2.60E-02 | 3 | P51854, P60891, P37837 | TKTL1, PRPS1, TALDO1 | More | |
| Nicergoline | hsa02010 | ABC transporters | 2.29E-02 | 2 | P45844, P08183 | ABCG1, ABCB1 | More | |
| Nicergoline | hsa03022 | Basal transcription factors | 3.32E-02 | 2 | O00268, Q15544 | TAF4, TAF11 | More | |
| Nicergoline | hsa03040 | Spliceosome | 6.28E-03 | 6 | Q14562, O43143, O60508, Q07955, Q01130, Q13243 | DHX8, DHX15, CDC40, SFRS1, SFRS2, SFRS5 | More | |
| Nicergoline | hsa04024 | cAMP signaling pathway | 4.38E-02 | 4 | P42338, P0DP23, Q13370, Q13009 | PIK3CB, CALM1, PDE3B, TIAM1 | More | |
| Nicergoline | hsa04060 | Cytokine-cytokine receptor interaction | 3.33E-02 | 8 | P48551, Q9UBD3, P47992, P02775, P09341, P32248, P51684, P01730 | IFNAR2, XCL2, XCL1, PPBP, CXCL1, CCR7, CCR6, CD4 | More | |
| Nicergoline | hsa04061 | Viral protein interaction with cytokine and cytokine receptor | 4.51E-03 | 6 | P51684, P32248, P09341, P02775, P47992, Q9UBD3 | CCR6, CCR7, CXCL1, PPBP, XCL1, XCL2 | More | |
| Nicergoline | hsa04064 | NF-kappa B signaling pathway | 2.99E-02 | 7 | O00463, P14778, Q13077, Q16548, Q8WV28, P24522, P09341 | TRAF5, IL1R1, TRAF1, BCL2A1, BLNK, GADD45A, CXCL1 | More | |
| Nicergoline | hsa04070 | Phosphatidylinositol signaling system | 4.86E-02 | 3 | P0DP23, P42338, P27987 | CALM1, PIK3CB, ITPKB | More | |
| Nicergoline | hsa04071 | Sphingolipid signaling pathway | 6.08E-04 | 5 | P21453, Q9H228, P01375, Q13362, Q9UQC2 | S1PR1, EDG8, TNF, PPP2R5C, GAB2 | More | |
| Nicergoline | hsa04080 | Neuroactive ligand-receptor interaction | 1.97E-02 | 5 | P28472, P21453, Q9H228, P21730, P07550 | GABRB3, S1PR1, EDG8, C5AR1, ADRB2 | More | |
| Nicergoline | hsa04120 | Ubiquitin mediated proteolysis | 1.08E-03 | 6 | Q9UBT2, Q14145, Q13042, P62837, Q15751, Q14669 | SAE2, KEAP1, CDC16, UBE2D2, HERC1, TRIP12 | More | |
| Nicergoline | hsa04140 | Autophagy - animal | 2.09E-02 | 4 | Q9NQL2, Q14643, P10415, Q04759 | RRAGD, ITPR1, BCL2, PRKCQ | More | |
| Nicergoline | hsa04210 | Apoptosis | 3.58E-02 | 4 | O76075, P01375, Q9NR28, Q16548 | DFFB, TNF, DIABLO, BCL2A1 | More | |
| Nicergoline | hsa04217 | Necroptosis | 2.34E-02 | 4 | P01375, P48023, Q14765, Q99878 | TNF, FASLG, STAT4, H2AC14 | More | |
| Nicergoline | hsa04261 | Adrenergic signaling in cardiomyocytes | 2.95E-02 | 4 | P07550, P22694, P18848, Q13362 | ADRB2, PRKACB, ATF4, PPP2R5C | More | |
| Nicergoline | hsa04340 | Hedgehog signaling pathway | 3.32E-02 | 2 | P49841, P22694 | GSK3B, PRKACB | More | |
| Nicergoline | hsa04360 | Axon guidance | 1.71E-02 | 4 | P20827, O95631, P42338, P23528 | EFNA1, NTN1, PIK3CB, CFL1 | More | |
| Nicergoline | hsa04380 | Osteoclast differentiation | 1.02E-02 | 6 | Q9UQC2, Q16539, P14778, O75015, P01375, Q8N149 | GAB2, MAPK14, IL1R1, FCGR3B, TNF, LILRA2 | More | |
| Nicergoline | hsa04530 | Tight junction | 3.29E-02 | 3 | P16989, P56750, Q14247 | CSDA, CLDN17, CTTN | More | |
| Nicergoline | hsa04612 | Antigen processing and presentation | 1.07E-03 | 6 | Q14953, P26715, P26717, Q13241, P01732, P01375 | KIR2DS5, KLRC1, KLRC2, KLRD1, CD8A, TNF | More | |
| Nicergoline | hsa04613 | Neutrophil extracellular trap formation | 2.18E-03 | 7 | P04908, Q93077, P62807, O60814, P68431, O43315, Q16539 | H2AC4; H2AC8, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12, AQP9, MAPK14 | More | |
| Nicergoline | hsa04625 | C-type lectin receptor signaling pathway | 3.87E-02 | 4 | Q9ULY5, P20749, P01375, Q16539 | CLEC4E, BCL3, TNF, MAPK14 | More | |
| Nicergoline | hsa04650 | Natural killer cell mediated cytotoxicity | 5.05E-04 | 7 | P01375, P20963, Q13241, P26718, P26717, Q14953, P26715 | TNF, CD247, KLRD1, KLRK1, KLRC2, KIR2DS5, KLRC1 | More | |
| Nicergoline | hsa04657 | IL-17 signaling pathway | 1.69E-05 | 8 | O00463, Q16539, P49841, P09341, P19875, P14780, P80188, P01375 | TRAF5, MAPK14, GSK3B, CXCL1, CXCL2, MMP9, LCN2, TNF | More | |
| Nicergoline | hsa04658 | Th1 and Th2 cell differentiation | 1.71E-02 | 5 | Q04759, P09693, P01730, P23771, P13765 | PRKCQ, CD3G, CD4, GATA3, HLA-DOB | More | |
| Nicergoline | hsa04659 | Th17 cell differentiation | 4.92E-03 | 9 | Q04759, P01730, P42224, P14784, P13765, P40189, P23771, P08238, P09693 | PRKCQ, CD4, STAT1, IL2RB, HLA-DOB, IL6ST, GATA3, HSP90AB1, CD3G | More | |
| Nicergoline | hsa04664 | Fc epsilon RI signaling pathway | 3.98E-02 | 3 | P01375, Q16539, Q9UQC2 | TNF, MAPK14, GAB2 | More | |
| Nicergoline | hsa04666 | Fc gamma R-mediated phagocytosis | 3.08E-02 | 3 | P42338, P23528, P14598 | PIK3CB, CFL1, NCF1 | More | |
| Nicergoline | hsa04668 | TNF signaling pathway | 2.12E-03 | 7 | P01375, O00463, Q16539, P18848, P19875, P20749, P14780 | TNF, TRAF5, MAPK14, ATF4, CXCL2, BCL3, MMP9 | More | |
| Nicergoline | hsa04714 | Thermogenesis | 5.21E-03 | 4 | Q16539, P33121, Q16718, O14521 | MAPK14, ACSL1, NDUFA5, SDHD | More | |
| Nicergoline | hsa04722 | Neurotrophin signaling pathway | 3.27E-02 | 3 | P49841, O43524, P48023 | GSK3B, FOXO3, FASLG | More | |
| Nicergoline | hsa04740 | Olfactory transduction | 2.52E-02 | 1 | Q9H255 | OR51E2 | More | |
| Nicergoline | hsa04742 | Taste transduction | 1.01E-02 | 1 | P30939 | HTR1F | More | |
| Nicergoline | hsa04910 | Insulin signaling pathway | 2.35E-02 | 3 | P22694, P06737, P49841 | PRKACB, PYGL, GSK3B | More | |
| Nicergoline | hsa04913 | Ovarian steroidogenesis | 2.54E-02 | 2 | P42330, P22694 | AKR1C3, PRKACB | More | |
| Nicergoline | hsa04914 | Progesterone-mediated oocyte maturation | 3.92E-02 | 3 | P42338, Q13370, P08238 | PIK3CB, PDE3B, HSP90AB1 | More | |
| Nicergoline | hsa04919 | Thyroid hormone signaling pathway | 7.11E-03 | 4 | P49841, P22694, O60244, Q9NVC6 | GSK3B, PRKACB, MED14, MED17 | More | |
| Nicergoline | hsa04924 | Renin secretion | 2.98E-03 | 4 | P22694, P07550, Q13370, P0DP23 | PRKACB, ADRB2, PDE3B, CALM1 | More | |
| Nicergoline | hsa04926 | Relaxin signaling pathway | 2.41E-02 | 4 | P18848, P22694, P14780, P30679 | ATF4, PRKACB, MMP9, GNA15 | More | |
| Nicergoline | hsa04927 | Cortisol synthesis and secretion | 2.54E-02 | 2 | P18848, P22694 | ATF4, PRKACB | More | |
| Nicergoline | hsa04931 | Insulin resistance | 1.94E-02 | 3 | P01375, P49841, P06737 | TNF, GSK3B, PYGL | More | |
| Nicergoline | hsa04932 | Non-alcoholic fatty liver disease | 2.44E-03 | 5 | P01375, P49841, P48023, Q16718, O14521 | TNF, GSK3B, FASLG, NDUFA5, SDHD | More | |
| Nicergoline | hsa04940 | Type I diabetes mellitus | 1.87E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nicergoline | hsa04966 | Collecting duct acid secretion | 2.52E-02 | 2 | P02730, Q9Y666 | SLC4A1, SLC12A7 | More | |
| Nicergoline | hsa04970 | Salivary secretion | 1.91E-02 | 3 | P07550, P22694, P49913 | ADRB2, PRKACB, CAMP | More | |
| Nicergoline | hsa04976 | Bile secretion | 1.67E-03 | 3 | O43315, P22694, P08183 | AQP9, PRKACB, ABCB1 | More | |
| Nicergoline | hsa05020 | Prion disease | 3.80E-02 | 4 | Q16718, O14521, P49841, Q16539 | NDUFA5, SDHD, GSK3B, MAPK14 | More | |
| Nicergoline | hsa05022 | Pathways of neurodegeneration - multiple diseases | 1.24E-02 | 6 | P49841, Q16718, O14521, Q13561, Q16539, Q08752 | GSK3B, NDUFA5, SDHD, DCTN2, MAPK14, PPID | More | |
| Nicergoline | hsa05031 | Amphetamine addiction | 4.32E-02 | 3 | P22694, P18848, Q13547 | PRKACB, ATF4, HDAC1 | More | |
| Nicergoline | hsa05034 | Alcoholism | 2.89E-03 | 4 | Q93077, P62807, O60814, P68431 | HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Nicergoline | hsa05120 | Epithelial cell signaling in Helicobacter pylori infection | 2.45E-02 | 4 | Q16539, P09341, P25024, P25025 | MAPK14, CXCL1, CXCR1, CXCR2 | More | |
| Nicergoline | hsa05140 | Leishmaniasis | 2.69E-02 | 5 | O75015, P13765, O60603, P49006, Q16539 | FCGR3B, HLA-DOB, TLR2, MARCKSL1, MAPK14 | More | |
| Nicergoline | hsa05143 | African trypanosomiasis | 2.72E-02 | 2 | P01375, P48023 | TNF, FASLG | More | |
| Nicergoline | hsa05144 | Malaria | 1.91E-02 | 3 | P01375, P35443, P26718 | TNF, THBS4, KLRK1 | More | |
| Nicergoline | hsa05146 | Amoebiasis | 3.33E-03 | 9 | P09341, P19875, P14778, P27930, P01375, O60603, P05089, P30679, P22694 | CXCL1, CXCL2, IL1R1, IL1R2, TNF, TLR2, ARG1, GNA15, PRKACB | More | |
| Nicergoline | hsa05160 | Hepatitis C | 1.27E-02 | 4 | P60033, P49841, P01375, P48023 | CD81, GSK3B, TNF, FASLG | More | |
| Nicergoline | hsa05163 | Human cytomegalovirus infection | 3.04E-03 | 8 | P01375, Q14643, P49841, P14778, P25025, Q16539, P04637, O00463 | TNF, ITPR1, GSK3B, IL1R1, CXCR2, MAPK14, TP53, TRAF5 | More | |
| Nicergoline | hsa05168 | Herpes simplex virus 1 infection | 1.15E-02 | 8 | P42224, Q07955, Q01130, Q13243, P42338, Q13398, Q03923, Q9UDV6 | STAT1, SFRS1, SFRS2, SFRS5, PIK3CB, ZNF211, ZNF85, ZNF212 | More | |
| Nicergoline | hsa05169 | Epstein-Barr virus infection | 4.06E-02 | 7 | P13765, P04637, P10415, P24522, P48551, P29728, P09693 | HLA-DOB, TP53, BCL2, GADD45A, IFNAR2, OAS2, CD3G | More | |
| Nicergoline | hsa05200 | Pathways in cancer | 3.92E-02 | 9 | P42338, P08238, P42224, P43246, P14923, O75293, P0DP23, P14784, P40189 | PIK3CB, HSP90AB1, STAT1, MSH2, JUP, GADD45B, CALM1, IL2RB, IL6ST | More | |
| Nicergoline | hsa05203 | Viral carcinogenesis | 4.85E-02 | 3 | Q15283, P62807, O60814 | RASA2, HIST1H2BC, H2BC12 | More | |
| Nicergoline | hsa05204 | Chemical carcinogenesis | 1.48E-02 | 2 | P78417, P11712 | GSTO1, CYP2C9 | More | |
| Nicergoline | hsa05205 | Proteoglycans in cancer | 3.68E-02 | 5 | P14780, P01375, P23588, Q13635, P22694 | MMP9, TNF, EIF4B, PTCH1, PRKACB | More | |
| Nicergoline | hsa05212 | Pancreatic cancer | 1.72E-02 | 3 | P42338, P42224, O75293 | PIK3CB, STAT1, GADD45B | More | |
| Nicergoline | hsa05213 | Endometrial cancer | 4.59E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | |
| Nicergoline | hsa05214 | Glioma | 2.03E-03 | 6 | P0DP23, Q16566, P42338, P04637, P24522, O75293 | CALM1, CAMK4, PIK3CB, TP53, GADD45A, GADD45B | More | |
| Nicergoline | hsa05216 | Thyroid cancer | 1.35E-02 | 3 | Q9UJU2, P04637, P24522 | LEF1, TP53, GADD45A | More | |
| Nicergoline | hsa05217 | Basal cell carcinoma | 3.97E-03 | 4 | Q13635, Q9UJU2, P04637, P24522 | PTCH1, LEF1, TP53, GADD45A | More | |
| Nicergoline | hsa05219 | Bladder cancer | 4.07E-02 | 2 | P14780, P04637 | MMP9, TP53 | More | |
| Nicergoline | hsa05224 | Breast cancer | 4.75E-02 | 4 | P49841, Q92837, P04637, P24522 | GSK3B, FRAT1, TP53, GADD45A | More | |
| Nicergoline | hsa05226 | Gastric cancer | 3.41E-02 | 5 | Q9UJU2, P04637, P24522, P14923, P10415 | LEF1, TP53, GADD45A, JUP, BCL2 | More | |
| Nicergoline | hsa05235 | PD-L1 expression and PD-1 checkpoint pathway in cancer | 4.55E-02 | 5 | O95267, P09693, O60603, Q16539, P01730 | RASGRP1, CD3G, TLR2, MAPK14, CD4 | More | |
| Nicergoline | hsa05321 | Inflammatory bowel disease | 1.91E-02 | 3 | P01375, Q14765, Q9UL17 | TNF, STAT4, TBX21 | More | |
| Nicergoline | hsa05322 | Systemic lupus erythematosus | 1.31E-04 | 5 | P09871, Q93077, P62807, O60814, P68431 | C1S, HIST1H2AC, HIST1H2BC, H2BC12, H3C1; H3C2; H3C3; H3C4; H3C6; H3C7; H3C8; H3C10; H3C11; H3C12 | More | |
| Nicergoline | hsa05330 | Allograft rejection | 2.72E-02 | 2 | P48023, P01375 | FASLG, TNF | More | |
| Nicergoline | hsa05332 | Graft-versus-host disease | 7.27E-04 | 4 | P48023, P01375, P26715, Q13241 | FASLG, TNF, KLRC1, KLRD1 | More | |
| Nicergoline | hsa05415 | Diabetic cardiomyopathy | 1.28E-02 | 4 | Q16718, O14521, Q16539, P49841 | NDUFA5, SDHD, MAPK14, GSK3B | More | |
| Nicergoline | hsa05418 | Fluid shear stress and atherosclerosis | 1.56E-05 | 12 | Q16539, P42338, Q14145, P14598, P10599, P14780, P01375, P04637, P14778, P27930, P0DP23, P08238 | MAPK14, PIK3CB, KEAP1, NCF1, TXN, MMP9, TNF, TP53, IL1R1, IL1R2, CALM1, HSP90AB1 | More | |
